Get the Stockscreener App
0.4354
7.12%
0.0153
After Hours:
.43
-0.0054
-1.24%
Shuttle Pharmaceuticals Holdings Inc stock is traded at $0.4354, with a volume of 746.44K.
It is up +7.12% in the last 24 hours and down -34.80% over the past month.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
See More
Previous Close:
$0.4201
Open:
$0.373
24h Volume:
746.44K
Relative Volume:
6.65
Market Cap:
$1.55M
Revenue:
-
Net Income/Loss:
$-7.35M
P/E Ratio:
-0.9465
EPS:
-0.46
Net Cash Flow:
$-5.48M
1W Performance:
-17.13%
1M Performance:
-34.80%
6M Performance:
-71.88%
1Y Performance:
+6.41%
1-Day Range:
$0.3601
$0.51
1-Week Range:
$0.3601
$0.5878
52-Week Range:
$0.2872
$3.30
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Company Profile
Name
Shuttle Pharmaceuticals Holdings Inc
Sector
Phone
(240) 403-4212
Address
401 PROFESSIONAL DRIVE, GAITHERSBURG
Compare SHPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SHPH
Shuttle Pharmaceuticals Holdings Inc
|
0.4354 | 1.55M | 0 | -7.35M | -5.48M | -0.46 |
|
ZTS
Zoetis Inc
|
161.67 | 71.94B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.94 | 47.16B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 46.33B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.48 | 18.69B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.25 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Latest News
This Md. biotech wants to get a cancer treatment to patients. It just tapped an industry outsider as co-CEO. - The Business Journals
Shuttle Pharma announces $5.75 million stock offering - Investing.com
Shuttle Pharma Secures Critical $5.75M Funding for Revolutionary Cancer Radiation Therapy - StockTitan
4 Artificial Intelligence (AI) Stocks Worth Buying in the Tech Sell-Off - The Globe and Mail
Lucid Group (LCID) Prepares to Sink Into Penny Stock Territory - The Globe and Mail
Shuttle Pharma appoints new interim co-CEO - Investing.com
Shuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEO - TipRanks
Shuttle Pharma Announces Appointment Of Christopher Cooper As Interim Co-CEO To Enhance Business Activities - Marketscreener.com
Shuttle Pharmaceuticals Appoints Christopher Cooper as Co-CEO - TipRanks
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities - GlobeNewswire
Shuttle Pharma Strengthens Leadership: New Co-CEO to Accelerate Growth While Phase 2 Trial Advances - StockTitan
SHPH stock touches 52-week low at $0.5 amid sharp annual decline - Investing.com Australia
SHPH stock touches 52-week low at $0.5 amid sharp annual decline By Investing.com - Investing.com South Africa
Zscaler: Bullish Pressure Builds, Rapid Price Increase Expected - The Globe and Mail
Shuttle Pharmaceuticals Holdings Offers Up To 10,000,000 Shares Of Common Stock -March 05, 2025 at 07:42 am EST - Marketscreener.com
Amendment: SEC Form S-1/A filed by Shuttle Pharmaceuticals Holdings Inc. - Quantisnow
Shuttle Pharmaceuticals Enters Revolving Loan Agreement - TipRanks
Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement -February 28, 2025 at 05:26 pm EST - Marketscreener.com
Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement - TradingView
3 Reasons to Sell RH and 1 Stock to Buy Instead - The Globe and Mail
SEC Form 424B3 filed by Shuttle Pharmaceuticals Holdings Inc. - Quantisnow
Shuttle Pharmaceuticals Amends Agreement with Alto Fund By Investing.com - Investing.com Australia
Shuttle Pharmaceuticals Amends Agreement with Alto Fund - Investing.com
SHPH stock touches 52-week low at $0.57 amid market challenges By Investing.com - Investing.com South Africa
SHPH stock touches 52-week low at $0.57 amid market challenges - Investing.com
Shuttle Pharma advances glioblastoma trial, expands diagnostics - Investing.com India
Shuttle Pharma advances glioblastoma trial, expands diagnostics By Investing.com - Investing.com South Africa
Shuttle Pharmaceuticals Holdings, Inc. Reports Progress on Phase 2 Trial and Diagnostic Advancements in Annual Update - Nasdaq
Shuttle Pharma Provides Corporate Update and Reports 2024 Results - GlobeNewswire
Can Shuttle Pharma's Glioblastoma Treatment Breakthrough Deliver Returns? CEO Bets $237K - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. SEC 10-K Report - TradingView
Why Five9 Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Contrasting Shuttle Pharmaceuticals (NASDAQ:SHPH) and Insmed (NASDAQ:INSM) - Defense World
Form S-1 Shuttle Pharmaceuticals - StreetInsider.com
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe - NewsBreak
Norwegian Air Shuttle ASA (NWARF) Expected to Announce Earnings on Thursday - Defense World
Badger Meter (BMI) Q4 Earnings Report Preview: What To Look For - The Globe and Mail
Shuttle Pharmaceuticals expands glioblastoma trial - MSN
Form 424B3 Shuttle Pharmaceuticals - StreetInsider.com
BlackRock MuniHoldings New York Quality Fund Enters Standstill Agreement with Saba Capital Management - Defense World
Cadre Holdings, Inc. (NYSE: CDRE) Enters Share Purchase Agreement with Carr’s Group PlcOn January 15, 2025, Cadre Holdings, Inc. (the “Company”) disclosed that it has entered into a Share Purchase Agreement with Carr’s Group Plc, selling all of the i - Defense World
GAN Limited Notifies of Non-Compliance with Nasdaq Listing RulesOn January 14, 2025, GAN Limited (NASDAQ: GAN) received a written notice from The Nasdaq Stock Market LLC stating that the company was not in compliance with Listing Rules 5620(a) a - Defense World
**Monster Beverage Corporation to Host Investor Meeting for Business Update**** - Defense World
Shuttle Pharmaceuticals Hits Milestone in Patient Enrollment for Phase 2 Clinical Trial - Defense World
Shuttle Pharma hits 25% mark in glioblastoma trial - MSN
Shuttle Pharma hits 25% mark in glioblastoma trial By Investing.com - Investing.com Australia
Shuttle Pharma Reaches Milestone in Patient Enrollment for - GlobeNewswire
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - Marketscreener.com
Shuttle Pharma Hits 25% Enrollment in Phase 2 Glioblastoma Trial for Promising Radiation Drug - StockTitan
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Wealth Enhancement Advisory Services LLC - Defense World
Shuttle Pharmaceuticals (NASDAQ:SHPH) Faces Potential Delisting from Nasdaq due to Minimum Bid Price Requirement Noncompliance - Defense World
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.78%
2.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):